-transparent.png){kind=logo}
Beta-adrenoceptor agonists such as albuterol are very effective in preventing exercise-induced asthma (EIA) when they are given as an aerosol immediately before exercise. However, their duration of protection against EIA is usually less than 2 h. This may be due partly to their rapid clearance from the airways. Salmeterol is a highly lipophylic compound that is thought to bind to an exoreceptor near the beta-receptor. The objective of this study was to compare the protective effect of salmeterol with albuterol against EIA. Exercise was performed 0.5, 2.5, 4.5, and 6.5 hours after administration of the active drugs. Subjects attended the laboratory on four days within six weeks and cycled for 8 min breathing dry compressed air. We studied 17 asthmatic subjects (aged 19 to 49 years) with moderate to severe EIA. Salmeterol (50 micrograms) or albuterol (200 micrograms) was given from a metered dose inhaler via a spacer (Volumatic). On the control day, the mean work load +/- 1 SD was 174 +/- 47 W, ventilation (VE) was 77.9 percent +/- 11.2 percent of the target ventilation (60 percent maximum voluntary ventilation [MVV]), and heart rate was 170 +/- 14 beats per minute. This intensity was maintained for all tests. FEV1 was measured before and after exercise and was expressed as percent predicted and as percentage of the preexercise value (percentage of fall). Thirty minutes after treatment, both drugs were effective in inhibiting EIA--percentage of fall in FEV1, 17 +/- 12 after salmeterol; percentage of fall in FEV1, 15 +/- 15 after albuterol. At 2.5, 4.5, and 6.5 hours, the reduction in FEV1 was significantly less (p less than 0.01) after salmeterol compared with albuterol. At 6.5 hours, the percentage of fall in FEV1 was 20 +/- 10 after salmeterol and 36 +/- 12 after albuterol. Salmeterol also had a more prolonged action as a bronchodilator and values for FEV1 were significantly higher compared with those on albuterol at 4.5 and 6.5 hours. At 6.5 hours, the FEV1 percent predicted was 96 +/- 10 after salmeterol and 84 +/- 12 after albuterol (p less than 0.01). We conclude that the extent of protection against EIA and the bronchodilation induced by both drugs was similar, but that salmeterol has a longer duration of action compared with albuterol. The reason for its superior duration of action may be due to a slower clearance of the drug from the airways.
S D Anderson, and
L T Rodwell, and
J Du Toit, and
I H Young
November 1995,
The European respiratory journal,
S D Anderson, and
L T Rodwell, and
J Du Toit, and
I H Young
August 1992,
Archives of disease in childhood,
S D Anderson, and
L T Rodwell, and
J Du Toit, and
I H Young
July 1983,
British journal of diseases of the chest,
S D Anderson, and
L T Rodwell, and
J Du Toit, and
I H Young
December 1990,
Lancet (London, England),
S D Anderson, and
L T Rodwell, and
J Du Toit, and
I H Young
July 1998,
Indian pediatrics,
S D Anderson, and
L T Rodwell, and
J Du Toit, and
I H Young
July 1994,
International journal of clinical pharmacology and therapeutics,
S D Anderson, and
L T Rodwell, and
J Du Toit, and
I H Young
December 1994,
American journal of respiratory and critical care medicine,
S D Anderson, and
L T Rodwell, and
J Du Toit, and
I H Young
May 2002,
The European respiratory journal,
S D Anderson, and
L T Rodwell, and
J Du Toit, and
I H Young
September 2000,
Annals of internal medicine,
S D Anderson, and
L T Rodwell, and
J Du Toit, and
I H Young
September 2000,
Annals of internal medicine,
